Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update. “In late 2021 we announced a st...
SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). Under the terms of the agreement, Biogen has returned the ri...
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it has retained Perella Weinberg Partners (PWP) as a financial advisor to assist the Company in exploring strategic alternatives. “Perella Weinberg Partners,...
Buying Penny Stocks Today? Here’s What You Need to Know After yesterday’s rather wild day of trading penny stocks and blue chips, what do we have in store for the stock market today? Well, there is a lot to keep track of right now as is the case with the stock market in ge...
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for CB 4332 for the treatment of Complement Factor I (CFI) deficiency (C...
The FDA has granted the orphan drug designation to Catalyst Biosciences (NASDAQ:CBIO) for its lead candidate marzeptacog alfa as a treatment for bleeding in patients with hemophilia A or B. With its orphan drug designation, the federal agency aims to offer financial incentives to dr...
Today, we revisit Catalyst Biosciences for the first time since this Spring. The stock has plunged recently after the company discontinued development of its lead pipeline candidate. The stock now sells for less than the cash on its balance sheet. Time to buy the dip? A f...
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29-D...
Gainers: Altamira (NASDAQ:CYTO) +68%. Wunong (NASDAQ:WNW) +52%. Everspin Technologies (NASDAQ:MRAM) +44%. SOC Telemed (NASDAQ:TLMD) +33%. Bit Brother (NASDAQ:BTB) +31%. Kura Sushi USA (NASDAQ:KRUS) +27%. Brilliant Earth Group (NASDAQ:BRLT) +26%. Xponential Fitness (NYSE:XPOF) +23%....
Gainers: Altamira Therapeutics (NASDAQ:CYTO) +82%, SOC Telemed (NASDAQ:TLMD) +16%, Sundial Growers (NASDAQ:SNDL) +16%, Beyond Air (NASDAQ:XAIR) +15%, IM Cannabis (NASDAQ:IMCC) +13%. Losers: Oncorus (NASDAQ:ONCR) -43%, Acutus Medical (NASD...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Biosciences Inc. Company Name:
CBIO Stock Symbol:
NASDAQ Market:
Catalyst Biosciences Inc. Website:
The combined company will operate as “Gyre Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “GYRE” effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq: CBIO) (“...
Catalyst Biosciences Inc. (CBIO) is expected to report $-0.05 for Q3 2023
NEW YORK, NY / ACCESSWIRE / March 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Broadmark Realty Capital Inc. (NYS...